- Croda launches Matrixyl Neolide, a peptide using a patented encapsulation for smarter delivery.
- Encapsulation provides controlled peptide release in cosmetic formulations for up to 15 days.
- Clinical results: 25% visible skin-firming improvement within two weeks.
- With microneedling it raised collagen III by 31%, and the ingredient is 99.79% natural, vegan, TFAs-free, RSPO-compliant with a 43% lower carbon footprint versus original Matrixyl.
Matrixyl Neolide technology
Matrixyl Neolide uses a patented encapsulation to protect the peptide in cosmetic formulations and release it gradually on skin, enabling controlled delivery for up to 15 days.
Clinical performance
Clinical data show a 25% visible skin‑firming improvement within two weeks; combined with microneedling it increased collagen III production by 31% versus microneedling alone and supported skin recovery.
Formulation and development impact
The controlled‑release system improves peptide stability and predictability, reduces formulation complexity, and supports repeatability, faster development timelines and commercial scale‑up.
Sustainability and compliance
The ingredient is 99.79% natural origin (ISO 16128), vegan suitable, free of trans fatty acids (TFAs), RSPO compliant and has a 43% lower carbon footprint compared with the original Matrixyl.
